CanonProtocol

CanonProtocol

TBA
2,138 Views
Canon Protocol is the world’s first fractional - algorithmic. The CNP Protocol introduced the world to the concept of a cryptocurrency being partially backed by collateral and partially stabilized algorithmically.
1.9
TOTAL SCORE
3.1
ICO PROFILE

(weight: 45%)

1
TEAM PROOF

(weight: 20%)

Get widget
General
Website: Visit
Dates: TBA
Country: Netherlands
Token info
Ticker: CNP
Platform: Binance Chain
Financial
ICO Price: 1 CNP = 1.5 USD
HEIGHT - 0px
WIDTH - 0px
PUT THIS CODE TO YOUR WEBSITE
ICO List
Other Interesting ICOs
Upcoming
MeFy
Mefy works on a subscription-based model, where the user of MeMe Care subscribes for yearly subscription allowing them any number of tests throughout the year for the cost of just consumables. Through its eConsult feature it connects worldwide doctors to worldwide patients thereby resolving accessibility issues and with its MeMe Edge device, it provides authenticity to the test conducted.
Upcoming
Cryptelo
Cryptelo is a blockchain-based encryption technology company that provides data transfer, collaboration, versioning, and storage services. Cryptelo Platform technology combines encryption and blockchain based key management that allows for data mirroring. This means users can share data by giving access, without it ever leaving their hands, and no third party can access and read data without permission.
Upcoming
ICOHeadStart
ICO HeadStart™ is the safest ICO fundraising platform in the world. Our experienced team of compliance experts award only carefully selected ICOs with a seal of approval after screening before these ICOs get listed on the ICO HeadStart™ platform adhering to give our community access to the best possible ICO proposals and the highest security standards in the ecosystem. In return for ETH and BTC the community receives MOAT along with voting points. Through voting the community decides which of these ICOs get funded. Elected projects receive their funds through Escrow 2.0 after the smart contract conditions have been met. ICO HeadStart's profits will be shared for 100%: 80% will be used to exchange back MOAT from the community and 20% will be used to give funded ICOs a head start. Decentralized, transparant, simple, honest.
Active
Tempo
Tempo is a French licensed, Paris-based, European-wide anchor for Stellar blockchain payments. The company offers online, offline and digital backed remittances to nearly 100 destination countries with over 300 physical agent locations. Tempo is creating the easiest, fastest and most secure bridge between cash and crypto.
Active
Review.Network
Review.Network is a project that aims to create a unique trusted high-intelligence user-company feedback platform based on blockchain and AI technologies. Review.Network provides direct communication between companies and customers, that helps carry on efficient top-tier market research feedback without any mediator. Our model also directly rewards participants for their valuable feedback. The platform's community can gain coins by producing content and working with quality reviews on the Review.Network platform. With the smart recommendation system implemented, it is easier for members to find the best goods and services with ease. The REW is the digital currency of the Review.Network platform. Companies purchase coins to conduct market research on the platform and reward users in exchange for the feedback they leave.
Upcoming
Pharmeum
Pharmeum is the world's first blockchain-based prescription platform with AI health analytics, which is currently working alongside the National Health Service (NHS) in England. The Pharmeum platform is an inter-operable, decentralised, digital prescription platform running over an intelligent neural network. Empowering patients’ ownership of their medication history, and enabling affordable access to healthcare globally. Medical errors and late diagnoses are minimised by using a permissioned blockchain integrated with artificial intelligence. Pharmeum is an advanced, digitised, health eco-system.The Pharmeum blockchain will improve medicine affordability, minimise errors, and create frictionless, quality care for patients.